Navigation Links
Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
Date:5/1/2008

MOUNTAIN VIEW, Calif., May 1 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it will present at the 161st American Psychiatric Association annual meeting the results of a Phase 2a clinical trial of Staccato(R) loxapine (AZ-004) for the treatment of acute agitation in schizophrenic patients. The poster presentation, "Inhaled Loxapine Rapidly Improves Acute Agitation in Schizophrenic Patients" (Presentation NR5-032), will be available for viewing at the meeting at the Washington Convention Center in Washington, D.C. on Tuesday, May 6, 2008 from 3:00 to 5:00 p.m. Eastern Time.

Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder are in Phase 2 testing. Prod
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... 21, 2014 Many power shifts are ... influence of patients in the biopharmaceutical market is ... more than ever, understanding how to effectively acquire, ... is essential. According to recent ... companies spent about two-thirds of their patient-focused dollars ...
(Date:11/21/2014)... , Nov. 21, 2014  The University of Maryland,s ... the ceremonial groundbreaking of the new A. James Clark ... new building will cultivate transformative new engineering and biomedical ... Taking place at 10:00 a.m. on November 21 at ... Branch Parking Lot, adjacent to the Jeong H. Kim ...
(Date:11/21/2014)...  Tandem Diabetes Care ® , Inc. (NASDAQ: ... and manufacturer of the t:slim ® Insulin ... non-profit dedicated to improving diabetes therapy management by ... diabetes data accessibility. This partnership will enable users ... development, to download and access data from their ...
Breaking Medicine Technology:New Report Details Importance of Adopting a "Patient Journey" Framework in Marketing 2University of Maryland Breaks Ground for A. James Clark Hall 2University of Maryland Breaks Ground for A. James Clark Hall 3University of Maryland Breaks Ground for A. James Clark Hall 4Tandem Diabetes Care Announces Partnership with Tidepool to Further Expand Access to Diabetes Device Data 2Tandem Diabetes Care Announces Partnership with Tidepool to Further Expand Access to Diabetes Device Data 3
...  Paragon Bioservices, Inc., a Baltimore-based CMO focused on ... today that it has been awarded a JVAP-CBMS ... the vaccine development and subsequent GMP manufacturing of ... The initial phase of the contract is ...
... Jan. 17, 2012 Roka Bioscience announced today that ... Performance Tested Method(SM) certification from the AOAC Research ... by Silliker, Inc., as part of the AOAC-RI independent ... Roka Listeria Detection Assay runs on the Atlas™ System, ...
Cached Medicine Technology:Paragon Bioservices Awarded Multi-Million Dollar DoD Contract for Filovirus Vaccine Development and Manufacturing 2Roka Bioscience Awarded AOAC-RI Certification for Roka Listeria Detection Assay 2
(Date:11/22/2014)... 22, 2014 “Greenfield Naturals” was featured ... Report , which features the latest and coolest technology ... and reporter for NewsWatch, conducted the product review and ... flavor of your water. , From pollution to hazardous ... that everything is done to remove these chemicals, especially ...
(Date:11/22/2014)... (HealthDay News) -- Many young people consider hookahs a ... study finds fumes from the water pipes contain the ... increased risk for leukemia in prior research, according to ... Cancer Epidemiology, Biomarkers & Prevention . "In ... not a safe alternative to smoking other forms of ...
(Date:11/22/2014)... HealthDay Reporter FRIDAY, Nov. 21, ... homes may commonly deal with aggressive or inappropriate behavior from ... 10 centers in New York state found that, in the ... were involved in some type of incident with a fellow ... someone yelling or cursing at another resident. In other cases, ...
(Date:11/21/2014)... 20, 2014 (HealthDay News) -- Seeking to make it ... Food and Drug Administration on Thursday approved a new ... Hydrocodone -- best known by the brand name Vicodin ... tied to a surge in dangerous addictions across the ... Hysingla ER (hydrocodone bitartrate) is an extended-release tablet to ...
(Date:11/21/2014)... November 21, 2014 Richard Wolfe, ... , will present advanced benefits administration strategies during ... Houston HR Leadership Summit. This Game Changer breakout ... industry to present cutting-edge solutions and best practices ... explain how real-time data exchange between health and ...
Breaking Medicine News(10 mins):Health News:An Easy Home Solution to Get Better Tasting Water was Featured on NewsWatch Television on October 30, 2014 2Health News:Hookahs Deliver Toxic Benzene in Every Puff, Study Shows 2Health News:Senior-to-Senior Aggression Common in U.S. Nursing Homes 2Health News:Senior-to-Senior Aggression Common in U.S. Nursing Homes 3Health News:FDA Approves 'Abuse-Resistant' Narcotic Painkiller 2Health News:FDA Approves 'Abuse-Resistant' Narcotic Painkiller 3Health News:Empyrean Benefit Solutions CEO Sharing Latest Benefits Administration Strategies with Houston HR Leaders 2Health News:Empyrean Benefit Solutions CEO Sharing Latest Benefits Administration Strategies with Houston HR Leaders 3
... difference between upbeat, less positive patients , , MONDAY, Oct. ... states predict how long a person with cancer will ... researchers say that among head and neck cancer patients, ... an independent factor affecting prognosis. , "We anticipated finding ...
... 2007; Company Prepares for ... Integration of Organon BioSciences, KENILWORTH, N.J., Oct. ... results for the third,quarter of 2007 and commented on its ... human health business,and Intervet animal health business. "Schering-Plough has ...
... Leading Employers Adopts InterviewDirect to ... Customer Support Positions, CHERRY HILL, N.J., ... provider of telephone-based job candidate screening solutions,today ... has selected,its InterviewDirect service to pre-qualify job ...
... (Oct. 22, 2007)Work done in part by researchers ... has led to the discovery of two genes that ... The findings are published in the Oct. 21 ... research on the genetic basis for common and complex ...
... bay, experts say , , SUNDAY, Oct. 21 (HealthDay News) -- ... a treat for both children and adults, according to experts ... Chicago. , "We can keep Halloween safe for everyone by ... senior vice president, said in a prepared statement. "Our vision ...
... new pledges of,commitment to invest in women,s ... and non-governmental organizations,today at closing sessions of ... mobilize political will and investment to reduce,pregnancy-related ... 1,800 participants from 109 countries cheered a ...
Cached Medicine News:Health News:Emotional State Doesn't Affect Cancer Survival 2Health News:Emotional State Doesn't Affect Cancer Survival 3Health News:Emotional State Doesn't Affect Cancer Survival 4Health News:Emotional State Doesn't Affect Cancer Survival 5Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 2Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 3Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 4Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 5Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 6Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 7Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 8Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 9Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 10Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 11Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 12Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 13Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 14Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 15Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 16Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 17Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 18Health News:Albert Einstein Healthcare Network Turns to InterviewDirect to Qualify Job Candidates 2Health News:Albert Einstein Healthcare Network Turns to InterviewDirect to Qualify Job Candidates 3Health News:UT rheumatologists discover 2 genes related to disabling form of arthritis 2Health News:UT rheumatologists discover 2 genes related to disabling form of arthritis 3Health News:Eye on Safety Makes Halloween Less Scary 2Health News:Women Deliver Conference Launches New Commitments 2
... The BOOKWALTER Retractor System represents ... retractor design available. Its wide array ... surgical specialites with a versatile system ... field.,Assembly is easy and uncomplicated, and ...
... ART Aerosol Resistant Tips offer a safe ... Tips are designed for applications such as ... In addition, ART Tips are excellent for ... forensic studies. ART Tips prevent aerosol contaminants ...
... disposable pipette tips, TowerPacks are ... Each Sterilized TowerPack is individually ... to help protect tips from ... the red sticker, which indicates ...
... wide orifice tip, the Finntip Wide is ... and macromolecules like genomic DNA. This tip ... fragmentation. It is excellent for use with ... the inside diameter of the orifice is ...
Medicine Products: